FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203913772> ?p ?o ?g. }

• W3203913772 endingPage "71" @default.
• W3203913772 startingPage "61" @default.
• W3203913772 abstract "In December 2020, the US Food and Drug Administration approved a 68Ga-labeled prostate-specific membrane antigen ligand (68Ga-PSMA-11) for positron emission tomography (PET) in patients with suspected prostate cancer (PCa) metastasis who are candidates for initial definitive therapy. 68Ga-PSMA PET is increasingly performed for these patients and is usually combined with computed tomography (CT). In recent years, 68Ga-PSMA PET has been combined with high-resolution magnetic resonance imaging (MRI), which is beneficial for T staging and may further enhance the staging of primary PCa.To compare the diagnostic accuracy of 68Ga-PSMA PET/MRI with 68Ga-PSMA PET/CT for staging of primary PCa.A comprehensive literature search was performed using Embase, PubMed/Medline, Web of Science, Cochrane Library, and Google Scholar up to June 24, 2021 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Risk of bias was assessed using the QUADAS-2 tool.The search identified 2632 articles, of which 27 were included. The diagnostic accuracy of 68Ga-PSMA PET/MRI, measured as the pooled natural logarithm of diagnostic odds ratio (lnDOR), was 2.27 (95% confidence interval [CI] 1.21-3.32) for detection of extracapsular extension (ECE), 3.50 (95% CI 2.14-4.86) for seminal vesicle invasion (SVI), and 4.73 (95% CI 2.93-6.52) for lymph node metastasis (LNM). For 68Ga-PSMA PET/CT, the analysis showed lnDOR of 2.45 (95% CI 0.75-4.14), 2.94 (95% CI 2.26-3.63), and 2.42 (95% CI 2.07-2.78) for detection of ECE, SVI, and LNM, respectively. The overall risk of bias and applicability concerns were assessed as moderate and low, respectively.68Ga-PSMA PET/MRI shows high diagnostic accuracy equivalent to that of 68Ga-PSMA PET/CT for detection of ECE, SVI, and LNM in staging of PCa. There is an urgent need for direct comparison of the two diagnostic tests in future research.The use of radioactively labeled molecules that bind to prostate-specific membrane antigen (68Ga-PSMA) for positron emission tomography (PET) scans combined with either computed tomography (CT) or magnetic resonance imaging (MRI) is increasing for prostate cancer diagnosis. There is a need for direct comparison of the two tests to demonstrate the benefit of 68Ga-PSMA PET/MRI for determining tumor stage in prostate cancer.After the recent US Food and Drug Administration approval of 68Ga-labeled prostate-specific membrane antigen ligand (68Ga-PSMA) positron emission tomography (PET) for staging of primary prostate cancer (PCa), it is expected that the use of this imaging modality will increase rapidly. Our review of the literature shows that 68Ga-PSMA PET/magnetic resonance imaging has high diagnostic accuracy equivalent to that of 68Ga-PSMA PET/computed tomography in primary PCa staging. There is an urgent need for direct head-to-head comparison of the two diagnostic tests in future research." @default.
• W3203913772 created "2021-10-11" @default.
• W3203913772 creator A5008500496 @default.
• W3203913772 creator A5009376752 @default.
• W3203913772 creator A5019559277 @default.
• W3203913772 creator A5047666215 @default.
• W3203913772 creator A5058941810 @default.
• W3203913772 creator A5059802956 @default.
• W3203913772 creator A5075546358 @default.
• W3203913772 date "2021-11-01" @default.
• W3203913772 modified "2023-10-09" @default.
• W3203913772 title "Comparison of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis" @default.
• W3203913772 cites W2107638293 @default.
• W3203913772 cites W2116511683 @default.
• W3203913772 cites W2147136637 @default.
• W3203913772 cites W2155421560 @default.
• W3203913772 cites W2160593693 @default.
• W3203913772 cites W2215968608 @default.
• W3203913772 cites W2313407248 @default.
• W3203913772 cites W2406375637 @default.
• W3203913772 cites W2410782911 @default.
• W3203913772 cites W2470255787 @default.
• W3203913772 cites W2557050169 @default.
• W3203913772 cites W2591849683 @default.
• W3203913772 cites W2592679547 @default.
• W3203913772 cites W2598902164 @default.
• W3203913772 cites W2618762583 @default.
• W3203913772 cites W2626115496 @default.
• W3203913772 cites W2767976593 @default.
• W3203913772 cites W2784001077 @default.
• W3203913772 cites W2804806782 @default.
• W3203913772 cites W2887423209 @default.
• W3203913772 cites W2888457361 @default.
• W3203913772 cites W2918536040 @default.
• W3203913772 cites W2926733161 @default.
• W3203913772 cites W2936831547 @default.
• W3203913772 cites W2937483840 @default.
• W3203913772 cites W2941509594 @default.
• W3203913772 cites W2945239299 @default.
• W3203913772 cites W2952904026 @default.
• W3203913772 cites W2971771201 @default.
• W3203913772 cites W2973091530 @default.
• W3203913772 cites W2989532516 @default.
• W3203913772 cites W2997987615 @default.
• W3203913772 cites W3003560173 @default.
• W3203913772 cites W3007640689 @default.
• W3203913772 cites W3015314953 @default.
• W3203913772 cites W3026360852 @default.
• W3203913772 cites W3033279546 @default.
• W3203913772 cites W3042999493 @default.
• W3203913772 cites W3045467104 @default.
• W3203913772 cites W3047122513 @default.
• W3203913772 cites W3047462110 @default.
• W3203913772 cites W3049756941 @default.
• W3203913772 cites W3086743023 @default.
• W3203913772 cites W3102689474 @default.
• W3203913772 cites W3122250961 @default.
• W3203913772 cites W3161533537 @default.
• W3203913772 cites W2178835360 @default.
• W3203913772 doi "https://doi.org/10.1016/j.euros.2021.09.006" @default.
• W3203913772 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8488242" @default.
• W3203913772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34632423" @default.
• W3203913772 hasPublicationYear "2021" @default.
• W3203913772 type Work @default.
• W3203913772 sameAs 3203913772 @default.
• W3203913772 citedByCount "6" @default.
• W3203913772 countsByYear W32039137722022 @default.
• W3203913772 countsByYear W32039137722023 @default.
• W3203913772 crossrefType "journal-article" @default.
• W3203913772 hasAuthorship W3203913772A5008500496 @default.
• W3203913772 hasAuthorship W3203913772A5009376752 @default.
• W3203913772 hasAuthorship W3203913772A5019559277 @default.
• W3203913772 hasAuthorship W3203913772A5047666215 @default.
• W3203913772 hasAuthorship W3203913772A5058941810 @default.
• W3203913772 hasAuthorship W3203913772A5059802956 @default.
• W3203913772 hasAuthorship W3203913772A5075546358 @default.
• W3203913772 hasBestOaLocation W32039137721 @default.
• W3203913772 hasConcept C121608353 @default.
• W3203913772 hasConcept C126322002 @default.
• W3203913772 hasConcept C126838900 @default.
• W3203913772 hasConcept C142724271 @default.
• W3203913772 hasConcept C143409427 @default.
• W3203913772 hasConcept C157481446 @default.
• W3203913772 hasConcept C20417620 @default.
• W3203913772 hasConcept C2775842073 @default.
• W3203913772 hasConcept C2776478404 @default.
• W3203913772 hasConcept C2780192828 @default.
• W3203913772 hasConcept C2908761598 @default.
• W3203913772 hasConcept C2989005 @default.
• W3203913772 hasConcept C44249647 @default.
• W3203913772 hasConcept C71924100 @default.
• W3203913772 hasConcept C95190672 @default.
• W3203913772 hasConceptScore W3203913772C121608353 @default.
• W3203913772 hasConceptScore W3203913772C126322002 @default.
• W3203913772 hasConceptScore W3203913772C126838900 @default.
• W3203913772 hasConceptScore W3203913772C142724271 @default.
• W3203913772 hasConceptScore W3203913772C143409427 @default.
• W3203913772 hasConceptScore W3203913772C157481446 @default.

• next